These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31981449)

  • 1. A 3-week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death.
    Briand F; Heymes C; Bonada L; Angles T; Charpentier J; Branchereau M; Brousseau E; Quinsat M; Fazilleau N; Burcelin R; Sulpice T
    Clin Transl Sci; 2020 May; 13(3):529-538. PubMed ID: 31981449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
    Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
    Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters.
    Briand F; Maupoint J; Brousseau E; Breyner N; Bouchet M; Costard C; Leste-Lasserre T; Petitjean M; Chen L; Chabrat A; Richard V; Burcelin R; Dubroca C; Sulpice T
    Metabolism; 2021 Apr; 117():154707. PubMed ID: 33444606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH.
    Baandrup Kristiansen MN; Veidal SS; Christoffersen C; Feigh M; Vrang N; Roth JD; Erickson M; Adorini L; Jelsing J
    BMC Gastroenterol; 2019 Dec; 19(1):228. PubMed ID: 31883514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH.
    Roth JD; Veidal SS; Fensholdt LKD; Rigbolt KTG; Papazyan R; Nielsen JC; Feigh M; Vrang N; Young M; Jelsing J; Adorini L; Hansen HH
    Sci Rep; 2019 Jun; 9(1):9046. PubMed ID: 31227742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating fibrosis and inflammation in an ex vivo NASH murine model.
    Gore E; Bigaeva E; Oldenburger A; Jansen YJM; Schuppan D; Boersema M; Rippmann JF; Broermann A; Olinga P
    Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G336-G351. PubMed ID: 31905025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
    Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
    Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
    [No Abstract]   [Full Text] [Related]  

  • 10. Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men.
    van den Hoek AM; Verschuren L; Caspers MPM; Worms N; Menke AL; Princen HMG
    Sci Rep; 2021 Mar; 11(1):5050. PubMed ID: 33658534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH.
    Boeckmans J; Buyl K; Natale A; Vandenbempt V; Branson S; De Boe V; Rogiers V; De Kock J; Rodrigues RM; Vanhaecke T
    Pharmacol Res; 2019 Jun; 144():377-389. PubMed ID: 31028903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model.
    Liu L; Liu C; Zhao M; Zhang Q; Lu Y; Liu P; Yang H; Yang J; Chen X; Yao Y
    PLoS One; 2020; 15(12):e0243911. PubMed ID: 33326461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
    Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
    J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice.
    Tsai HC; Chang FP; Li TH; Liu CW; Huang CC; Huang SF; Yang YY; Lee KC; Hsieh YC; Wang YW; Lee TY; Huang YH; Hou MC; Lin HC
    Biomed Res Int; 2019; 2019():6740616. PubMed ID: 31321239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis.
    Tølbøl KS; Stierstorfer B; Rippmann JF; Veidal SS; Rigbolt KTG; Schönberger T; Gillum MP; Hansen HH; Vrang N; Jelsing J; Feigh M; Broermann A
    Dig Dis Sci; 2019 May; 64(5):1238-1256. PubMed ID: 30511198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis.
    Perakakis N; Stefanakis K; Feigh M; Veidal SS; Mantzoros CS
    Liver Int; 2021 Aug; 41(8):1853-1866. PubMed ID: 33788377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
    Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
    Nestor JJ; Parkes D; Feigh M; Suschak JJ; Harris MS
    Sci Rep; 2022 Apr; 12(1):6666. PubMed ID: 35461369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.